Hector Izurieta, MD, MPH

FDA
Center for Biologics Evaluation and Research
Washington D.C, DC
USA
Biographical Sketch:
Dr. Izurieta worked five years in Africa with MSF (Doctors without Borders) and other International organizations. He subsequently worked at CDC on vaccine-preventable diseases for ten years, four of which were spent in a detail to the Pan American Health Organization (PAHO), where he played a leading role in their successful efforts to eliminate indigenous measles transmission from the Western Hemisphere. He joined FDA in 2003. Dr. Izurieta has over 15 years experience in the field of vaccines, vaccine adverse events, and vaccine preventable diseases. He has approximate 40 publications in scientific journals. Selected publications: 1. Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet (online), October 31, 2009. 2. Slade B, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta H et al. Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine. Accepted for publication by JAMA. 3. Haber P, Patel M, Izurieta HS et al. Post-licensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006--September 25, 2007. Pediatrics 2008; 121(6):1206-1212. 4. Braun MM, Izurieta HS, Ball R. Effectiveness of influenza vaccine. NEJM 2007;2728-31-Correspondence. 5. Tapiainen T. Prevots R, Izurieta HS et al. Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007;25:5793-5802. 17574313 6. Izurieta HS, Haber, P, Wise, RP et al. Adverse events reported following live, cold –adapted intranasal influenza vaccine. JAMA 294(21):: 2720-25, 2005. 7. de Quadros CA, Izurieta H, Venczel L, Carrasco P. Measles eradication in the Americas: progress to date.J Infect Dis. 2004 May 1;189 Suppl 1:S227-35. 8. Izurieta, HS, Thompson, WW, Kramarz, P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med.2000 Jan 27;342(4):232-9. 9. Mounts AW, Kwong H, Izurieta HS et al. Case-control study of risk factors for avian influenza A(H5N1) disease, Hong Kong, 1997. J Infect Dis.1999 Aug;180(2):505-8. 10. Izurieta HS, Strebel PM, Blake PA. Post-licensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997 Nov 12;278(18):1495-9.